SCHEMBL5721802

SCHEMBL5721802

O=C(NO)c1ccc(C(=O)N2CCC3(CC2)OCCO3)s1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
HPGD P15428 6/20 0.53
USP2 O75604 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 3/20 0.48
GAA P10253 3/20 0.48
KMT2A Q03164 3/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
GLA P06280 1/20 0.48
MAPT P10636 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.48
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5721928 0.81 HPGD (0.81) ALDH1A1HPGDSMN1; SMN2NPC1GAA
SCHEMBL5721732 0.79 HPGD (0.67) ALDH1A1HPGDGAAMAPTHSD17B10
SCHEMBL5721869 0.78 HDAC3 (0.54) ALDH1A1HPGDNPC1RAB9AKDM4E
SCHEMBL19396254 0.71 KMT2A (0.50) ALDH1A1HPGDUSP2SMN1; SMN2NPC1
SCHEMBL5721886 0.70 MAPT (0.68) ALDH1A1HPGDUSP2KMT2AMEN1
SCHEMBL5721752 0.70 HPGD (0.61) ALDH1A1HPGDNPC1KMT2ARAB9A
SCHEMBL2077811 0.70 POLB (0.67) ALDH1A1HPGDSMN1; SMN2NPC1GAA
SCHEMBL1587973 0.70 HPGD (0.76) ALDH1A1HPGDSMN1; SMN2NPC1GAA
SCHEMBL5195904 0.69 POLB (0.65) ALDH1A1HPGDUSP2SMN1; SMN2GAA
SCHEMBL5721942 0.69 TSHR (0.51) ALDH1A1HPGDSMN1; SMN2NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784173-B2 ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-08-31 US claimed
US-20030013757-A1 Aromatic dicarboxylic acid derivatives HOFFMANN-LA ROCHE INC. 2003-01-16 US claimed
EP-1401824-B1 AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS HOFFMANN LA ROCHE (CH) 2006-10-25 EP disclosed
US-20040214862-A1 Aromatic dicarboxylic acid derivatives LESER-REIFF ULRIKE 2004-10-28 US disclosed
US-6784173-B2 ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-08-31 US disclosed
EP-1401824-A2 AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS F. Hoffman-la Roche AG (CH) 2004-03-31 EP disclosed
WO-2003011851-A2 AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS F. HOFFMAN-LA ROCHE AG (CH) 2003-02-13 WO disclosed
US-20030013757-A1 Aromatic dicarboxylic acid derivatives HOFFMANN-LA ROCHE INC. 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214862-A1 Aromatic dicarboxylic acid derivatives HDAC1, HDAC2, HDAC11 ALDH1A1 71/4885HPGD 1631/4885USP2 2200/4885
US-20030013757-A1 Aromatic dicarboxylic acid derivatives HDAC1, HDAC2, HDAC11 ALDH1A1 71/4885HPGD 1631/4885USP2 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.